Evidence map›Paper›PMID 34469552›Full record

ArticleThe Journal of infectious diseases2021

Pneumococcal Carriage in Burkina Faso After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Results From 2 Cross-sectional Population-Based Surveys.

Lassané Kaboré, Tolulope Adebanjo, Berthe Marie Njanpop-Lafourcade, Soumeya Ouangraoua, Felix T Tarbangdo, Bertrand Meda, Srinivasan Velusamy, Brice Bicaba, Flavien Aké, Lesley McGee and 7 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 5 countries.

Lassané KaboréAgence de Médecine Préventive, Ouagadougou, Burkina Faso.
Tolulope AdebanjoNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Berthe Marie Njanpop-LafourcadeAgence de Médecine Préventive, Ouagadougou, Burkina Faso.
Soumeya OuangraouaCentre Muraz, Bobo-Dioulasso, Burkina Faso.
Felix T TarbangdoDavycas International, Ouagadougou, Burkina Faso.
Bertrand MedaAgence de Médecine Préventive, Ouagadougou, Burkina Faso.
Srinivasan VelusamyNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Brice BicabaMinistère de la Santé, Ouagadougou, Burkina Faso.
Flavien AkéDavycas International, Ouagadougou, Burkina Faso.
Lesley McGeeNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Seydou YaroCentre Muraz, Bobo-Dioulasso, Burkina Faso.
Edouard BetsemAgence de Médecine Préventive, Ouagadougou, Burkina Faso.
Alain GervaixDepartment of Pediatrics, University Hospitals of Geneva, Geneva, Switzerland.
Bradford D GessnerAgence de Médecine Préventive, Paris, France.
Cynthia G WhitneyNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Jennifer C MoïsiPfizer, Paris, France.
Chris A Van BenedenNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Centers for Disease Control and Prevention · USCentre Muraz · BFInternational Institute for Water and Environmental Engineering · BFMinistère De La Santé · BFNational Center for Immunization and Respiratory Diseases · USPfizer (France) · FRPfizer (United States) · USUniversité de Yaoundé I · CMUniversity Hospital of Geneva · CHUniversity of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBurkina Faso, a country in Africa's meningitis belt, introduced 13-valent pneumococcal conjugate vaccine (PCV13) in October 2013, with 3 primary doses given at 8, 12 and 16 weeks of age. To assess whether the new PCV13 program controlled pneumococcal carriage, we evaluated overall and serotype-specific colonization among children and adults during the first 3 years after introduction.

methodsWe conducted 2 population-based, cross-sectional, age-stratified surveys in 2015 and 2017 in the city of Bobo-Dioulasso. We used standardized questionnaires to collect sociodemographic, epidemiologic, and vaccination data. Consenting eligible participants provided nasopharyngeal (all ages) and oropharyngeal (≥5 years only) swab specimens. Swab specimens were plated onto blood agar either directly (2015) or after broth enrichment (2017). Pneumococci were serotyped by conventional multiplex polymerase chain reaction. We assessed vaccine effect by comparing the proportion of vaccine-type (VT) carriage among colonized individuals from a published baseline survey (2008) with each post-PCV survey.

resultsWe recruited 992 (2015) and 1005 (2017) participants. Among children aged <5 years, 42.8% (2015) and 74.0% (2017) received ≥2 PCV13 doses. Among pneumococcal carriers aged <1 year, VT carriage declined from 55.8% in 2008 to 36.9% in 2017 (difference, 18.9%; 95% confidence interval, 1.9%-35.9%; P = .03); among carriers aged 1-4 years, VT carriage declined from 55.3% to 31.8% (difference, 23.5%; 6.8%-40.2%; P = .004); and among participants aged ≥5 years, no significant change was observed.

conclusionWithin 3 years of PCV13 implementation in Burkina Faso, we documented substantial reductions in the percentage of pneumococcal carriers with a VT among children aged <5 years, but not among persons aged ≥5 years. More time, a change in the PCV13 schedule, or both, may be needed to better control pneumococcal carriage in this setting.

Indexed as

Pneumococcal VaccinesStreptococcus pneumoniaeVaccines, ConjugateBurkina FasoCarrier StateChild, PreschoolCross-Sectional StudiesFemaleHumansInfantInfant, NewbornMaleNasopharynxPneumococcal InfectionsPopulation SurveillanceSerogroupPneumococcal VaccinesVaccines, ConjugateBurkina Fasocarriagepneumococcal conjugate vaccineserotypesStreptococcus pneumoniaesurvey

Identifiers

PMID34469552
PMCPMC8409529
OpenAlexW3196762161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.